Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 1
2015 2
2016 4
2017 5
2018 2
2019 2
2020 5
2021 3
2022 4
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
NK cells propagate T cell immunity following in situ tumor vaccination.
Jin WJ, Jagodinsky JC, Vera JM, Clark PA, Zuleger CL, Erbe AK, Ong IM, Le T, Tetreault K, Berg T, Rakhmilevich AL, Kim K, Newton MA, Albertini MR, Sondel PM, Morris ZS. Jin WJ, et al. Among authors: erbe ak. Cell Rep. 2023 Dec 26;42(12):113556. doi: 10.1016/j.celrep.2023.113556. Epub 2023 Dec 13. Cell Rep. 2023. PMID: 38096050 Free PMC article.
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Pascual-Pasto G, McIntyre B, Shraim R, Buongervino SN, Erbe AK, Zhelev DV, Sadirova S, Giudice AM, Martinez D, Garcia-Gerique L, Dimitrov DS, Sondel PM, Bosse KR. Pascual-Pasto G, et al. Among authors: erbe ak. J Immunother Cancer. 2022 Dec;10(12):e004704. doi: 10.1136/jitc-2022-004704. J Immunother Cancer. 2022. PMID: 36460335 Free PMC article.
Roles of CD4+ T cells as mediators of antitumor immunity.
Kravtsov DS, Erbe AK, Sondel PM, Rakhmilevich AL. Kravtsov DS, et al. Among authors: erbe ak. Front Immunol. 2022 Sep 9;13:972021. doi: 10.3389/fimmu.2022.972021. eCollection 2022. Front Immunol. 2022. PMID: 36159781 Free PMC article. Review.
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung JT, London WB, Shulkin BL, Mathew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park J, Yu AL, Sondel PM, Bagatell R. Erbe AK, et al. J Immunother Cancer. 2023 Feb;11(2):e006530. doi: 10.1136/jitc-2022-006530. J Immunother Cancer. 2023. PMID: 36822669 Free PMC article.
Short-course neoadjuvant in situ vaccination for murine melanoma.
Aiken TJ, Komjathy D, Rodriguez M, Stuckwisch A, Feils A, Subbotin V, Birstler J, Gillies SD, Rakhmilevich AL, Erbe AK, Sondel PM. Aiken TJ, et al. Among authors: erbe ak. J Immunother Cancer. 2022 Jan;10(1):e003586. doi: 10.1136/jitc-2021-003586. J Immunother Cancer. 2022. PMID: 35039460 Free PMC article.
43 results